Crescita Therapeutics Inc. (TSX:CTX)
0.4600
0.00 (0.00%)
Aug 22, 2025, 3:50 PM EDT
Crescita Therapeutics Revenue
Crescita Therapeutics had revenue of 6.23M CAD in the quarter ending June 30, 2025, with 52.47% growth. This brings the company's revenue in the last twelve months to 20.27M, up 20.33% year-over-year. In the year 2024, Crescita Therapeutics had annual revenue of 19.58M with 11.75% growth.
Revenue (ttm)
20.27M
Revenue Growth
+20.33%
P/S Ratio
0.43
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.68M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.58M | 2.06M | 11.75% |
Dec 31, 2023 | 17.52M | -6.00M | -25.52% |
Dec 31, 2022 | 23.53M | 6.76M | 40.29% |
Dec 31, 2021 | 16.77M | 1.13M | 7.22% |
Dec 31, 2020 | 15.64M | -6.70M | -29.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Curaleaf Holdings | 1.75B |
Green Thumb Industries | 1.57B |
Trulieve Cannabis | 1.62B |
Sienna Senior Living | 929.68M |
dentalcorp Holdings | 1.62B |
Cronos Group | 177.69M |
WELL Health Technologies | 1.12B |
Extendicare | 1.51B |
Crescita Therapeutics News
- 16 days ago - Crescita Reports Second Quarter 2025 Results - Business Wire
- 2 months ago - Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders - Financial Post
- 2 months ago - Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders - Business Wire
- 3 months ago - Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis® - Financial Post
- 3 months ago - Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis® - Business Wire
- 3 months ago - Crescita Reports First Quarter 2025 Results - Business Wire
- 5 months ago - Crescita Therapeutics GAAP EPS of -C$0.01, revenue of C$6.9M - Seeking Alpha
- 10 months ago - Crescita Reports Third Quarter 2024 Results - Business Wire